Portnoy Mark L. 4

4 · CRYO CELL INTERNATIONAL INC · Filed Aug 29, 2022

Form 4

Period: 2022-08-25

DirectorCo-CEO10% Owner

Transactions

Exercise/Conversion
Stock Option
2022-08-25$3.14/sh+59,459$186,701→ 0 total
Exercise: $3.14From: 2016-04-15Exp: 2026-04-15→ Common Stock (59,459 underlying)
Exercise/Conversion
Common Stock
2022-08-25$3.14/sh+59,459$186,701→ 821,973 total

Holdings

Stock Option
Exercise: $7.92From: 2018-03-08Exp: 2023-03-08→ Common Stock (20,000 underlying)
20,000
Stock Option
Exercise: $13.50From: 2021-12-22Exp: 2024-12-22→ Common Stock (20,000 underlying)
20,000
Stock Option
Exercise: $7.53From: 2019-08-30Exp: 2029-08-30→ Common Stock (22,222 underlying)
22,222
Common Stock
(indirect: By 401(k))
42,266
Common Stock
(indirect: By Partnership)
71,529
Stock Option
Exercise: $7.28From: 2019-12-20Exp: 2029-12-20→ Common Stock (20,000 underlying)
20,000
Stock Option
Exercise: $12.27From: 2021-12-22Exp: 2028-12-22→ Common Stock (100,000 underlying)
100,000

Footnotes (4)

[F1]Shares of Common Stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark L. Portnoy may be deemed the beneficial owner as its general partner.
[F2]The stock options are subject to the approval of the 2022 Equity Incentive Plan, which vote is expected to occur at the Company's 2022 Annual Meeting.
[F3]One-third of the stock options will vest on December 22, 2022, one-third will vest on December 22, 2023 and one-third on December 22, 2024.
[F4]Stock options vest immediately if the price of the Company's stock reaches $25.00 per share during the seven-year option term.

Documents

1 file